This is a preview of subscription content, log in via an institution to check access.
Notes
Sponsored by Merck Sharp & Dohme Corp.
2010 values
Reference
Elbasha EH, et al. Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis c virus genotype 1 infection in Portugal. Applied Health Economics and Health Policy : 26 Jan 2013. Available from: URL: http://dx.doi.org/10.1007/s40258-012-0007-8
Rights and permissions
About this article
Cite this article
Boceprevir a cost-effective addition in HCV therapy. PharmacoEcon Outcomes News 671, 8 (2013). https://doi.org/10.1007/s40274-013-0141-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0141-z